Background: Lopinavir/ritonavir is a common protease inhibitor (PI) used for second-line regimens in children. Several studies have shown higher plasma concentrations of antiretroviral agents in Thai adults than in Caucasians, suggesting that lower doses may be used.
Introduction
Lopinavir/ritonavir is a protease inhibitor (PI) combination licensed for use in HIV-infected adults and children. It is widely used in children because of the convenience of ritonavir co-formulation, potent virological and immunological efficacy and its availability in a paediatric oral solution. PI-based highly active antiretroviral therapy (HAART) is indicated for children who fail first-line non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens and those who may have nevirapine resistance from exposure to single-dose nevirapine given to prevent mother-to-child transmission. 1 The WHO paediatric treatment guidelines recommend lopinavir/ritonavir as the preferred PI in these settings. 2 However, due to its cost, lopinavir/ ritonavir-based HAART puts a high financial burden on access programmes in developing countries.
Besides cost, other concerns are the lopinavir/ritonavir-induced metabolic and morphological changes. With the longevity of HIV-infected patients, this may be an additional concern for children. Associations between lopinavir plasma concentrations and lipid changes have been suggested. Patients achieving higher lopinavir trough concentrations (C trough ) may be at greater risk for dyslipidaemia. 3 Potentially both cost and toxicity can be decreased when reduced doses of PIs can be administered. Several pharmacokinetic studies in Asian HIV-infected adults have shown that even if the PI dose is decreased by half, Thais display similar plasma PI concentrations to Caucasians on a standard dose. 4, 5 These studies changed clinical practice for saquinavir and indinavir in Thailand, where they are dosed, with ritonavir boosting at 1500/ 100 mg once daily and 400/100 mg twice daily, respectively. 6, 7 The HIV-NAT 019 study with low-dose lopinavir/ritonavir (266 mg/66 mg; the standard dose is 400 mg/100 mg) in Thai adults demonstrated adequate lopinavir plasma concentrations. 8 For children, few data concerning low-dose PIs exist. There was a study of pharmacokinetics of ritonavir-boosted indinavir in 19 Thai children showing that the lower dose of 220-300 mg/m 2 (the standard dose is 400/125 mg/m 2 of indinavir/ritonavir) 9 provided adequate trough concentrations. 10 Data from 19 Thai children taking a standard lopinavir/ritonavir dose (230/57.5 mg/m 2 ) in combination with saquinavir demonstrated a higher lopinavir C trough of 5.9 mg/L compared with 3.4 mg/L in US children who used the same dose. 11 Therefore, we conducted a pilot study to evaluate the pharmacokinetics of low-dose lopinavir/ritonavir in Thai HIV-infected children. This may lead to appropriate lopinavir dosing for children in the region in an attempt to reduce cost and long-term adverse events.
Materials and methods
This randomized, open-label, prospective study was conducted at the HIV Netherlands Australia Thailand Research collaboration (HIV-NAT), and the Department of Pediatrics, Chulalongkorn University, Bangkok, Thailand. The study was approved by Chulalongkorn University Ethics Committee and all caregivers gave written informed consent prior to enrolment. The clinical trial number of the study is NCT00887120.
The trial enrolled 24 HIV-infected children aged 2-18 years who were antiretroviral therapy (ART) experienced but PI naive with baseline plasma HIV RNA .1000 copies/mL. The exclusion criteria were taking any medication that has been reported to have a drug interaction with lopinavir, such as rifampicin, efavirenz and nevirapine. The children were stratified according to body weight (,17 kg, 17 to ,30 kg and 30 kg). Subjects were randomized in a 1:1 ratio within each stratum to receive the WHO-recommended lopinavir dose according to the WHO guidelines (Table 1) 12 or low-dose lopinavir (70% of the standard lopinavir dose based on results from the HIV-NAT 019 study).
8 Lopinavir oral solution containing lopinavir/ritonavir 80/20 mg/mL was used in all cases prior to the pharmacokinetic study at week 4. After the pharmacokinetic study, children who had poor tolerability to lopinavir/ritonavir oral solution were allowed to switch to the lopinavir/ritonavir (133/33 mg) soft gel capsule if they could swallow pills. Since tenofovir has not been approved in children, and enteric-coated didanosine is not included in the National AIDS Program due to its high cost, the combination of zidovudine and lamivudine was chosen as the nucleoside reverse transcriptase inhibitor (NRTI) backbone. Zidovudine and lamivudine were used at standard doses (zidovudine 180-240 mg/m 2 /dose twice daily and lamivudine 4 mg/kg twice daily). For subjects who exhibited inadequate response to therapy, defined as HIV RNA reduction ,1 log 10 at week 24, the NRTI backbone was modified based on genotypic results.
After baseline assessment, children attended clinical follow-up visits at weeks 4, 8, 12, 24, 36 and 48. The physical examination and evaluation of HIV-related illness and adverse events were performed at each study visit. Adverse events were graded according to the Division of AIDS, US National Institutes of Health. 13 Laboratory analyses including haematology, clinical chemistry and fasting lipid profiles, CD4 count and percentage (FACS Calibur, Becton Dickinson, San Jose, CA, USA), HIV RNA (Roche Amplicor Ultrasensitive assay, Palo Alto, CA, USA) and therapeutic drug monitoring (TDM) of the lopinavir and ritonavir level were performed at weeks 12, 24 and 48. Genotypic resistance testing was performed at baseline and at weeks 24 and 48 if HIV RNA was .1000 copies/mL.
The adherence to treatment was evaluated by pill counts and history taking. Early intervention, such as a home visit or frequent telephone follow-up, was implemented in children with potential adherence problems. 
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A 12 h pharmacokinetic assessment was performed 4-6 weeks after starting the trial medication. Plasma samples were collected during a 12 h interval at pre-dose and 2, 4, 6, 8, 10 and 12 h after drug intake. Medication was taken under observation with standardized meals. Blood samples were centrifuged at 3000 rpm at 208C for 10 min. The samples were kept at 208C for no more than 14 days prior to analysis. Plasma concentrations of lopinavir and ritonavir were measured by a validated HPLC method. 14 The lopinavir level was linear over the range of 0.1-30.0 mg/L. The percentage accuracy was found to be 101% at 0.14 mg/L, 99% at 1.4 mg/L and 101% at 6.8 mg/L. The lower limit of quantification for lopinavir is 0.1 mg/L. The HIV-NAT laboratory participates in an international quality control and quality assessment programme and has been cross-validated with other pharmacokinetic laboratories. 15 Lopinavir and ritonavir pharmacokinetic parameters were analysed using WinNonlin software (version 5.0.1, Pharsight Corporations, Mountain View, CA, USA) by a non-compartmental analysis model and included AUC 0 -12 (mg . h/L), C max (mg/L), C trough (mg/L), T max (h) and t 1/2 (h). Lopinavir plasma concentration was considered subtherapeutic when ,1.0 mg/L. 16 
Statistical analysis
Statistical analysis was performed with SAS version 9.1 and SPSS version 15.0. Baseline demographic and clinical characteristics were compared between groups with non-parametric models. The coefficient of variance was calculated by dividing the standard deviation by the mean. Associations between variables, including age, weight and lopinavir AUC 0 -12 and C trough , were examined by linear regression. Statistical tests were two-tailed and performed at the overall 0.05 level of significance. Efficacy data were analysed using intent-to-treat analysis and on-treatment analysis. This study was designed as a pilot study; therefore a sample size of 12 children per arm was used.
Results

Baseline characteristics
From April 2007 to January 2008, 24 children were enrolled. The baseline characteristics are shown in Table 2 . The median age and weight were 9.5 years [interquartile range (IQR) -51) , respectively. The distribution of children among the weight bands is listed in Table 1 . During the study period, there were 12 (50%) children (8 in the standard arm and 4 in the low-dose arm) who switched from oral solution to soft gel capsule due to poor tolerability at a median time of 25.5 weeks.
Pharmacokinetics
Two children were excluded from the pharmacokinetic analysis due to adherence, documented by pill count and history taking, of ,80%, and the lopinavir level at pre-dose below the lower limit of quantification (one in each arm). The plasma lopinavir concentration -time curves among children who received standard and low-dose lopinavir are shown in Figure 1 . Table 3 summarizes the pharmacokinetic parameters for lopinavir and ritonavir. The AUC 0 -12 and C trough were reduced by 29% (83.8 versus 117.6 mg . h/L) and 31% (3.4 versus 4.9 mg/L), respectively, in the low-dose arm. The pharmacokinetic parameters of lopinavir and ritonavir were not statistically significantly different between the two arms. None of the lopinavir C trough values was below the efficacy threshold of 1.0 mg/L, but one patient from the low-dose group did show a pre-dose concentration of ,1.0 mg/L. There was no correlation between AUC 0 -12 and age (r ¼ 20.17, P ¼ 0.434) or body weight (r ¼ 20.21, P ¼ 0.317) (Figure 2) .
Eighteen (75%) children reported good adherence to their treatment throughout the study period (67% and 83% in the standard and low-dose arms, respectively). The median (IQR) levels of the lopinavir TDM C trough of 18 children at weeks 12, 24 and 48 were 7.4 (5.7-9.0), 7.4 (4.7 -10.3) and 8.2 (3.6 -11.3) mg/L among children in the standard arm and 4.2 (2.6 -6.3), 3.3 (2.8 -4.4) and 3.1 (3.0 -4.7) mg/L among children in the low-dose arm. Only at week 24 did the low-dose arm have significantly lower lopinavir C trough compared with the standard arm (P ¼ 0.04).
Clinical, immunological and virological efficacy
The overall median (IQR) body weight and height change at week 48 from baseline was 2.4 kg (1.5-3.7) and 5.0 cm (3.0-6.5), with no statistically significant difference between arms. At week 48, the median CD4 percentage was significantly increased from 15% (12% -23%) to 22% (15% -28%) in the standard arm (P ¼ 0.02) and from 17% (8% -25%) to 27% (21% -31%) in the low-dose arm (P¼ 0.001). Intention-to-treat analysis showed that 50% and 67% of children in the standard and low-dose arms achieved HIV RNA ,50 copies/mL at week 24, compared with 50% and 83% at week 48. For the on-treatment analysis, we excluded six children who had adherence problems (four in the standard arm and two in the low-dose arm). At week 24, 63% 
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and 80% of children in the standard arm and the low-dose arm achieved HIV RNA ,50 copies/mL; and 75% versus 100% at week 48. Lopinavir C trough of two children in the standard arm who did not achieve viral suppression was far below 1.0 mg/L, supporting non-adherence even though self-reported adherence and pill count were adequate. The patients who were nonadherent (n ¼ 6) were significantly older than those who adhered to treatment (P¼ 0.05). Genotypic resistance testing was performed on seven patients with HIV RNA .1000 copies/mL after week 24. Four children had no additional mutation, one had two new NRTI mutations, one had two minor PI mutations and one had three new NRTI mutations, with one minor PI mutation.
Safety and tolerability
There were eight episodes of hospitalization in three children, all in the low-dose arm, and none related to the study treatment. One child had four episodes of acute diarrhoea and one episode of acute bronchitis, one child with underlying spastic cerebral palsy had viral gastroenteritis and one child had dengue haemorrhagic fever. There were seven reported adverse events that were rated as possibly or probably related to lopinavir (four in the standard arm and three in the low-dose arm). These were five cases of diarrhoea, one case of flatulence and one case of hair loss.
At baseline a significant difference was observed in triglycerides between the two groups in favour of the standard dose (78 versus 112 mg/dL). At week 48, the median triglyceride levels were 109 mg/dL (IQR 89 -170) and 162 mg/dL (IQR 126-188) for children in the standard arm and the low-dose arm, respectively, P .0.05. The median cholesterol levels were 185 mg/dL (IQR 156 -203) and 173 mg/dL (IQR 150-205) for children in the standard arm and the low-dose arm, respectively, P .0.05.
Discussion
This pilot study showed that the pharmacokinetic parameters were adequate in Thai children who received either the low dose or the standard dose of lopinavir, and no differences in efficacy and safety between the two groups at 48 weeks were observed.
In this pharmacokinetic pilot study, we assessed if low-dose lopinavir/ritonavir provided adequate lopinavir drug exposure in HIV-infected Thai children compared with the standard lopinavir/ritonavir dose. At the steady-state 12 h sampling, all but one had lopinavir plasma concentrations above the recommended efficacy threshold of .1.0 mg/L 16 throughout the dosing interval. The lopinavir exposure AUC and C trough in the low-dose arm were reduced by 29% and 31%, respectively, compared with the standard-dose arm, which is similar to the magnitude of the dose reduction. When comparing the pharmacokinetic parameters from this study with those of the HIV-NAT 019 study in Thai adults (who received lopinavir/ritonavir 400 mg/100 mg), the children who received the standard dose achieved a similar AUC 12 of 117 mg . h/L compared with 119 mg . h/L in the adult study. Interestingly, even though the low-dose arm in both studies had similar lopinavir dose reductions to 70% of the standard dose, the lopinavir AUC 12 was higher in the paediatric population; 83 mg . h/L versus 68 mg . h/L in adults. Because the exposure of lopinavir in plasma is thought to be dependent on ritonavir dose, 17, 18 the similar ritonavir AUC 12 among children in the low-dose arm compared with the standard arm may have contributed to higher lopinavir AUC 12 in our study.
Pharmacokinetic data for children on the standard dose given in the package insert of Kaletra w (AUC 12 72 mg . h/L and C trough 3.4 mg/L) are comparable to the values in our children on low-dose lopinavir. The C trough of the standard group was particularly high at weeks 12, 24 and 48 even when compared with another Thai paediatric cohort, where an average C trough of 5.5 mg/L was reported. 19 Thai children seem to have higher exposure to lopinavir compared with other ethnicities, although a head-to-head comparative study has never been carried out. Pharmacogenomics have been proposed as a cause for differences in drug metabolism between ethnicities. 20 For example, efavirenz metabolism is strongly related to the CYP2B6 516G.T polymorphism. The children who had the T/T genotype had significantly higher efavirenz levels. 21 Lopinavir is a substrate of the P-glycoprotein (ABCB1) transporter, encoded by the polymorphic ABCB1 gene. There was a study to investigate the impact of three common exonic ABCB1 polymorphisms, ABCB1 1236C.T, 2667G.T/A and 3435C.T genotypes; however, there were no associations to predict plasma lopinavir level. 22 In this study, even though there were few patients in each body weight band and age group, there was no correlation between pharmacokinetic parameters and body weight or age.
We found good efficacy of lopinavir/ritonavir-based HAART in the two groups despite recycling of NRTIs with overall viral suppression rates of 67% for intention-to-treat analysis and 89% for on-treatment analysis. This is comparable to other second-line and salvage therapy studies. Sáez-Llorens et al. 23 reported a 79% viral suppression (defined as ,400 copies) after 48 weeks. In a study by Delaugerre et al., 24 a viral suppression rate of 52% at week 48 was found (,50 copies/mL); the majority of the children were PI experienced, resulting in poorer outcome. It was shown that lower lopinavir levels in this PI-experienced group predicted higher virological failure rates. Therefore, lower dose lopinavir should not be an option for children who have failed previous PI therapy but should rather be limited to children who are PI naive. An alternative second-line option using double-boosted PI has been explored in PI-naive children with multiple TAMs (thymidine analogue mutations) with a similar virological suppression rate. 19 In addition, our data on low-dose lopinavir do not apply to infants who require higher lopinavir dose due to higher drug clearance. 25 In this study, six patients admitted non-adherence and two were highly suspected for non-adherence. Age seems to be the main risk factor for non-adherence, similar to reports from PACTG219C in American children and adolescents. 26 The liquid formulation, with its poor taste, may also have affected the adherence. Lopinavir tablets are now available that are easier for children to take and could possibly improve adherence. A study in Thai adults using standard-dose lopinavir showed that the mean C trough was higher with the tablet compared with the soft gel formulation. 27 This may give us a better option for future dose reduction trials. In this small study, we did not see a toxicity benefit of the lower lopinavir dose in terms of clinical adverse events and lipids. At present there is only a potential 30% reduction in cost benefit.
In conclusion, treatment with low-dose lopinavir resulted in an adequate pharmacokinetic profile and efficacy compared with standard-dose lopinavir in Thai children. Our data need to be confirmed in a larger randomized trial of standard-dose versus low-dose lopinavir. The public health impact for reducing toxicity and cost in treating children with HIV could be significant.
